Unlocking the potential of nanocarrier-mediated mRNA delivery across diverse biomedical frontiers: A comprehensive review

被引:2
作者
Pawar, Smita [1 ]
Pingale, Prashant [2 ]
Garkal, Atul [3 ,4 ,5 ]
Osmani, Riyaz Ali M. [6 ]
Gajbhiye, Kavita [7 ]
Kulkarni, Madhur [8 ]
Pardeshi, Krutika [9 ]
Mehta, Tejal [3 ]
Rajput, Amarjitsing [7 ]
机构
[1] Inst Chem Technol, Dept Pharmaceut Sci & Technol, NP Marg, Mumbai 400019, Maharashtra, India
[2] GESs Sir Dr M S Gosavi Coll Pharmaceut Educ & Res, Dept Pharmaceut, Nasik 422005, Maharashtra, India
[3] Nirma Univ, Inst Pharm, Dept Pharmacol, Ahmadabad 382481, Gujarat, India
[4] Johns Hopkins Univ, Sch Med, Ctr Nanomed, Wilmer Eye Inst, Baltimore, MD 21231 USA
[5] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21231 USA
[6] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut, Mysuru 570015, Karnataka, India
[7] Bharti Vidyapeeth Deemed Univ, Poona Coll Pharm, Dept Pharmaceut, Bharti Vidyapeeth Educ Complex, Pune 411038, Maharashtra, India
[8] SCESs Indira Coll Pharm, New Pune Mumbai Highway, Pune 411033, Maharashtra, India
[9] Sandip Univ, Sch Pharmaceut Sci, Dept Pharmacol, Nasik 422213, Maharashtra, India
关键词
Nanocarriers; mRNA; Gene delivery; Vesicular systems; LIPID NANOPARTICLE FORMULATIONS; SMALL INTERFERING RNA; IN-VIVO; GENE DELIVERY; INTRACELLULAR DELIVERY; SYSTEMIC DELIVERY; CARBON NANOTUBES; DENDRITIC CELLS; SIRNA DELIVERY; POLYMERIC NANOPARTICLES;
D O I
10.1016/j.ijbiomac.2024.131139
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Messenger RNA (mRNA) has gained marvelous attention for managing and preventing various conditions like cancer, Alzheimer's, infectious diseases, etc. Due to the quick development and success of the COVID-19 mRNAbased vaccines, mRNA has recently grown in prominence. A lot of products are in clinical trials and some are already FDA-approved. However, still improvements in line of optimizing stability and delivery, reducing immunogenicity, increasing efficiency, expanding therapeutic applications, scalability and manufacturing, and long-term safety monitoring are needed. The delivery of mRNA via a nanocarrier system gives a synergistic outcome for managing chronic and complicated conditions. The modified nanocarrier-loaded mRNA has excellent potential as a therapeutic strategy. This emerging platform covers a wide range of diseases, recently, several clinical studies are ongoing and numerous publications are coming out every year. Still, many unexplained physical, biological, and technical problems of mRNA for safer human consumption. These complications were addressed with various nanocarrier formulations. This review systematically summarizes the solved problems and applications of nanocarrier-based mRNA delivery. The modified nanocarrier mRNA meaningfully improved mRNA stability and abridged its immunogenicity issues. Furthermore, several strategies were discussed that can be an effective solution in the future for managing complicated diseases.
引用
收藏
页数:25
相关论文
共 297 条
  • [101] Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA
    Islam, Mohammad Ariful
    Xu, Yingjie
    Tao, Wei
    Ubellacker, Jessalyn M.
    Lim, Michael
    Aum, Daniel
    Lee, Gha Young
    Zhou, Kun
    Zope, Harshal
    Yu, Mikyung
    Cao, Wuji
    Oswald, James Trevor
    Dinarvand, Meshkat
    Mahmoudi, Morteza
    Langer, Robert
    Kantoff, Philip W.
    Farokhzad, Omid C.
    Zetter, Bruce R.
    Shi, Jinjun
    [J]. NATURE BIOMEDICAL ENGINEERING, 2018, 2 (11): : 850 - 864
  • [102] The promise of mRNA vaccines: a biotech and industrial perspective
    Jackson, Nicholas A. C.
    Kester, Kent E.
    Casimiro, Danilo
    Gurunathan, Sanjay
    DeRosa, Frank
    [J]. NPJ VACCINES, 2020, 5 (01)
  • [103] Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
    Jayaraman, Muthusamy
    Ansell, Steven M.
    Mui, Barbara L.
    Tam, Ying K.
    Chen, Jianxin
    Du, Xinyao
    Butler, David
    Eltepu, Laxman
    Matsuda, Shigeo
    Narayanannair, Jayaprakash K.
    Rajeev, Kallanthottathil G.
    Hafez, Ismail M.
    Akinc, Akin
    Maier, Martin A.
    Tracy, Mark A.
    Cullis, Pieter R.
    Madden, Thomas D.
    Manoharan, Muthiah
    Hope, Michael J.
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2012, 51 (34) : 8529 - 8533
  • [104] Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
  • [105] Suppression of RNA recognition by Toll-like receptors:: The impact of nucleoside modification and the evolutionary origin of RNA
    Karikó, K
    Buckstein, M
    Ni, HP
    Weissman, D
    [J]. IMMUNITY, 2005, 23 (02) : 165 - 175
  • [106] mRNA is an endogenous ligand for Toll-like receptor 3
    Karikó, K
    Ni, HP
    Capodici, J
    Lamphier, M
    Weissman, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) : 12542 - 12550
  • [107] Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
    Kariko, Katalin
    Muramatsu, Hiromi
    Welsh, Frank A.
    Ludwig, Janos
    Kato, Hiroki
    Akira, Shizuo
    Weissman, Drew
    [J]. MOLECULAR THERAPY, 2008, 16 (11) : 1833 - 1840
  • [108] Karikó K, 2007, CURR OPIN DRUG DISC, V10, P523
  • [109] Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin
    Kariko, Katalin
    Muramatsu, Hiromi
    Keller, Jason M.
    Weissman, Drew
    [J]. MOLECULAR THERAPY, 2012, 20 (05) : 948 - 953
  • [110] Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
    Kariko, Katalin
    Muramatsu, Hiromi
    Ludwig, Janos
    Weissman, Drew
    [J]. NUCLEIC ACIDS RESEARCH, 2011, 39 (21) : e142